$ALXN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALEXION PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ALEXION PHARMACEUTICALS, INC.. Get notifications about new insider transactions in ALEXION PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 3 4 5 6 7 8 9 10 11 ... 22 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 27 2014 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Option Exercise | M | 49.43 | 1,393 | 68,856 | 0 | |
Aug 27 2014 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Option Exercise | M | 24.36 | 3,659 | 89,133 | 0 | |
Aug 27 2014 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Sell | S | 170.53 | 5,052 | 861,518 | 12,786 | 17.8 K to 12.8 K (-28.32 %) |
Aug 27 2014 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Buy | M | 49.43 | 1,393 | 68,856 | 17,838 | 16.4 K to 17.8 K (+8.47 %) |
Aug 27 2014 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Buy | M | 24.36 | 3,659 | 89,133 | 16,445 | 12.8 K to 16.4 K (+28.62 %) |
Aug 18 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 17.65 | 35,000 | 617,750 | 32,047 | |
Aug 18 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 17.65 | 35,000 | 617,750 | 67,047 | |
Aug 18 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 170.06 | 35,000 | 5,952,100 | 1,027,186 | 1.1 M to 1 M (-3.30 %) |
Aug 18 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 17.65 | 35,000 | 617,750 | 1,062,186 | 1 M to 1.1 M (+3.41 %) |
Aug 18 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 167.02 | 1,278 | 213,452 | 1,027,186 | 1 M to 1 M (-0.12 %) |
Aug 18 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 166.40 | 15,570 | 2,590,848 | 1,028,464 | 1 M to 1 M (-1.49 %) |
Aug 18 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 165.44 | 18,152 | 3,003,067 | 1,044,034 | 1.1 M to 1 M (-1.71 %) |
Aug 18 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 17.65 | 35,000 | 617,750 | 1,062,186 | 1 M to 1.1 M (+3.41 %) |
Aug 13 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 17.65 | 24,542 | 433,166 | 102,047 | |
Aug 13 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 17.65 | 80,458 | 1,420,084 | 126,589 | |
Aug 13 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 163.74 | 6,711 | 1,098,859 | 1,027,186 | 1 M to 1 M (-0.65 %) |
Aug 13 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 162.88 | 6,008 | 978,583 | 1,033,897 | 1 M to 1 M (-0.58 %) |
Aug 13 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 161.91 | 8,076 | 1,307,585 | 1,039,905 | 1 M to 1 M (-0.77 %) |
Aug 13 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 161.08 | 3,747 | 603,567 | 1,047,981 | 1.1 M to 1 M (-0.36 %) |
Aug 13 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 17.65 | 24,542 | 433,166 | 1,051,728 | 1 M to 1.1 M (+2.39 %) |
Aug 13 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 160.61 | 27,633 | 4,438,136 | 1,027,186 | 1.1 M to 1 M (-2.62 %) |
Aug 13 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 159.92 | 52,825 | 8,447,774 | 1,054,819 | 1.1 M to 1.1 M (-4.77 %) |
Aug 13 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 17.65 | 80,458 | 1,420,084 | 1,107,644 | 1 M to 1.1 M (+7.83 %) |
Aug 05 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 157.42 | 1,662 | 261,632 | 106,944 | 108.6 K to 106.9 K (-1.53 %) |
Aug 05 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 158.00 | 1,349 | 213,142 | 118,616 | 120 K to 118.6 K (-1.12 %) |
Aug 05 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 157.88 | 5,145 | 812,293 | 1,027,186 | 1 M to 1 M (-0.50 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 17.65 | 20,489 | 361,631 | 207,047 | |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 17.65 | 1,200 | 21,180 | 227,536 | |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 17.65 | 105,600 | 1,863,840 | 228,736 | |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 167.14 | 2,800 | 467,992 | 1,032,331 | 1 M to 1 M (-0.27 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 166.42 | 4,010 | 667,344 | 1,035,131 | 1 M to 1 M (-0.39 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 165.18 | 13,679 | 2,259,497 | 1,039,141 | 1.1 M to 1 M (-1.30 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 17.65 | 20,489 | 361,631 | 1,052,820 | 1 M to 1.1 M (+1.98 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 164.93 | 1,200 | 197,916 | 1,032,331 | 1 M to 1 M (-0.12 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 17.65 | 1,200 | 21,180 | 1,033,531 | 1 M to 1 M (+0.12 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 166.12 | 1,000 | 166,120 | 1,032,331 | 1 M to 1 M (-0.10 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 164.72 | 1,000 | 164,720 | 1,033,331 | 1 M to 1 M (-0.10 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 163.81 | 8,747 | 1,432,846 | 1,034,331 | 1 M to 1 M (-0.84 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 162.76 | 34,768 | 5,658,840 | 1,043,078 | 1.1 M to 1 M (-3.23 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 162.01 | 50,737 | 8,219,901 | 1,077,846 | 1.1 M to 1.1 M (-4.50 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 160.93 | 9,348 | 1,504,374 | 1,128,583 | 1.1 M to 1.1 M (-0.82 %) |
Jul 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 17.65 | 105,600 | 1,863,840 | 1,137,931 | 1 M to 1.1 M (+10.23 %) |
Aug 05 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 157.82 | 1,525 | 240,676 | 162,770 | 164.3 K to 162.8 K (-0.93 %) |
Aug 05 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Sell | S | 158.23 | 184 | 29,114 | 16,576 | 16.8 K to 16.6 K (-1.10 %) |
Jul 24 2014 | ALXN | ALEXION PHARMACEUT ... | Mollen John T | Director | Grant | A | 0.00 | 768 | 0 | 830 | 62 to 830 (+1,238.71 %) |
Jul 24 2014 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Option Exercise | A | 167.97 | 2,706 | 454,527 | 2,706 | |
Jul 24 2014 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Grant | A | 0.00 | 768 | 0 | 768 | 0 to 768 |
Jul 24 2014 | ALXN | ALEXION PHARMACEUT ... | BURNS M MICHELE | Director | Option Exercise | A | 167.97 | 2,706 | 454,527 | 2,706 | |
Jul 24 2014 | ALXN | ALEXION PHARMACEUT ... | BURNS M MICHELE | Director | Grant | A | 0.00 | 768 | 0 | 768 | 0 to 768 |
Jul 24 2014 | ALXN | ALEXION PHARMACEUT ... | Brennan David R | Director | Option Exercise | A | 167.97 | 2,706 | 454,527 | 2,706 | |
Jul 24 2014 | ALXN | ALEXION PHARMACEUT ... | Brennan David R | Director | Grant | A | 0.00 | 768 | 0 | 768 | 0 to 768 |
Jun 23 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 11.92 | 90,280 | 1,076,138 | 0 | |
Jun 23 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 165.92 | 2,134 | 354,073 | 1,032,331 | 1 M to 1 M (-0.21 %) |
Jun 23 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 165.10 | 31,476 | 5,196,688 | 1,034,465 | 1.1 M to 1 M (-2.95 %) |
Jun 23 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 164.11 | 17,896 | 2,936,913 | 1,065,941 | 1.1 M to 1.1 M (-1.65 %) |
Jun 23 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 163.17 | 16,240 | 2,649,881 | 1,083,837 | 1.1 M to 1.1 M (-1.48 %) |
Jun 23 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 162.06 | 11,449 | 1,855,425 | 1,100,077 | 1.1 M to 1.1 M (-1.03 %) |
Jun 23 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 161.09 | 3,585 | 577,508 | 1,111,526 | 1.1 M to 1.1 M (-0.32 %) |
Jun 23 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 159.96 | 7,500 | 1,199,700 | 1,115,111 | 1.1 M to 1.1 M (-0.67 %) |
Jun 23 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 11.92 | 90,280 | 1,076,138 | 1,122,611 | 1 M to 1.1 M (+8.75 %) |
Jun 13 2014 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Option Exercise | M | 104.86 | 25,000 | 2,621,500 | 75,000 | |
Jun 13 2014 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 167.40 | 3,993 | 668,428 | 24,426 | 28.4 K to 24.4 K (-14.05 %) |
Jun 13 2014 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 166.35 | 15,949 | 2,653,116 | 28,419 | 44.4 K to 28.4 K (-35.95 %) |
Jun 13 2014 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 165.88 | 5,058 | 839,021 | 44,368 | 49.4 K to 44.4 K (-10.23 %) |
Jun 13 2014 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Buy | M | 104.86 | 25,000 | 2,621,500 | 49,426 | 24.4 K to 49.4 K (+102.35 %) |
Jun 06 2014 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Sell | S | 170.01 | 1,236 | 210,132 | 4,682 | 5.9 K to 4.7 K (-20.89 %) |
Jun 06 2014 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Option Exercise | M | 96.35 | 3,425 | 329,999 | 0 | |
Jun 06 2014 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Sell | S | 170.00 | 3,425 | 582,250 | 12,276 | 15.7 K to 12.3 K (-21.81 %) |
Jun 06 2014 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Buy | M | 96.35 | 3,425 | 329,999 | 15,701 | 12.3 K to 15.7 K (+27.90 %) |
May 29 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 11.92 | 70,000 | 834,400 | 90,280 | |
May 29 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 166.95 | 8,444 | 1,409,726 | 1,032,331 | 1 M to 1 M (-0.81 %) |
May 29 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 166.45 | 35,348 | 5,883,675 | 1,040,775 | 1.1 M to 1 M (-3.28 %) |
May 29 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 165.52 | 26,208 | 4,337,948 | 1,076,123 | 1.1 M to 1.1 M (-2.38 %) |
May 29 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 11.92 | 70,000 | 834,400 | 1,102,331 | 1 M to 1.1 M (+6.78 %) |
May 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 11.92 | 9,720 | 115,862 | 160,280 | |
May 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 10.29 | 60,280 | 620,281 | 0 | |
May 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 158.14 | 300 | 47,442 | 1,032,331 | 1 M to 1 M (-0.03 %) |
May 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 157.09 | 3,675 | 577,306 | 1,032,631 | 1 M to 1 M (-0.35 %) |
May 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 156.30 | 27,557 | 4,307,159 | 1,036,306 | 1.1 M to 1 M (-2.59 %) |
May 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 155.60 | 38,468 | 5,985,621 | 1,063,863 | 1.1 M to 1.1 M (-3.49 %) |
May 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 11.92 | 9,720 | 115,862 | 1,102,331 | 1.1 M to 1.1 M (+0.89 %) |
May 22 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 10.29 | 60,280 | 620,281 | 1,092,611 | 1 M to 1.1 M (+5.84 %) |
May 15 2014 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 160.85 | 3,574 | 574,878 | 24,426 | 28 K to 24.4 K (-12.76 %) |
May 15 2014 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Option Exercise | M | 16.83 | 12,276 | 206,605 | 0 | |
May 15 2014 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 160.78 | 12,276 | 1,973,735 | 4,840 | 17.1 K to 4.8 K (-71.72 %) |
May 15 2014 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Buy | M | 16.83 | 12,276 | 206,605 | 17,116 | 4.8 K to 17.1 K (+253.64 %) |
May 07 2014 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Option Exercise | A | 159.70 | 2,785 | 444,765 | 2,785 | |
May 07 2014 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Option Exercise | A | 159.70 | 2,785 | 444,765 | 2,785 | |
May 07 2014 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Option Exercise | A | 159.70 | 2,785 | 444,765 | 2,785 | |
May 07 2014 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Option Exercise | A | 159.70 | 2,785 | 444,765 | 2,785 | |
May 07 2014 | ALXN | ALEXION PHARMACEUT ... | Mollen John T | Director | Option Exercise | A | 159.70 | 2,785 | 444,765 | 2,785 | |
May 07 2014 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Option Exercise | A | 159.70 | 2,785 | 444,765 | 2,785 | |
May 07 2014 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Option Exercise | A | 159.70 | 2,785 | 444,765 | 2,785 | |
Apr 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 10.29 | 66,210 | 681,301 | 60,280 | |
Apr 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | M | 10.29 | 3,790 | 38,999 | 126,490 | |
Apr 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 157.15 | 12,241 | 1,923,673 | 1,032,331 | 1 M to 1 M (-1.17 %) |
Apr 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 156.58 | 32,014 | 5,012,752 | 1,044,572 | 1.1 M to 1 M (-2.97 %) |
Apr 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 155.31 | 21,955 | 3,409,831 | 1,076,586 | 1.1 M to 1.1 M (-2.00 %) |
Apr 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 10.29 | 66,210 | 681,301 | 1,098,541 | 1 M to 1.1 M (+6.41 %) |
Apr 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 155.12 | 3,790 | 587,905 | 1,032,331 | 1 M to 1 M (-0.37 %) |
Apr 30 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Buy | M | 10.29 | 3,790 | 38,999 | 1,036,121 | 1 M to 1 M (+0.37 %) |
Mar 13 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Option Exercise | M | 10.84 | 30,000 | 325,200 | 0 | |
Mar 13 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Option Exercise | M | 8.18 | 30,000 | 245,400 | 0 | |
Mar 13 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Sell | S | 179.88 | 10,000 | 1,798,800 | 179,217 | 189.2 K to 179.2 K (-5.28 %) |
Mar 13 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Sell | S | 178.35 | 50,000 | 8,917,500 | 189,217 | 239.2 K to 189.2 K (-20.90 %) |
Mar 13 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Buy | M | 10.84 | 30,000 | 325,200 | 239,217 | 209.2 K to 239.2 K (+14.34 %) |
Mar 13 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Buy | M | 8.18 | 30,000 | 245,400 | 209,217 | 179.2 K to 209.2 K (+16.74 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Veneman Ann M | Director | Grant | A | 0.00 | 895 | 0 | 6,813 | 5.9 K to 6.8 K (+15.12 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Grant | A | 0.00 | 895 | 0 | 13,181 | 12.3 K to 13.2 K (+7.28 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Grant | A | 0.00 | 895 | 0 | 5,735 | 4.8 K to 5.7 K (+18.49 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | NORBY R DOUGLAS | Director | Grant | A | 0.00 | 895 | 0 | 32,676 | 31.8 K to 32.7 K (+2.82 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | MATHIS LARRY | Director | Grant | A | 0.00 | 895 | 0 | 30,351 | 29.5 K to 30.4 K (+3.04 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | MADRI JOSEPH A | Director | Grant | A | 0.00 | 895 | 0 | 180,212 | 179.3 K to 180.2 K (+0.50 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | KELLER WILLIAM R | Director | Grant | A | 0.00 | 895 | 0 | 13,171 | 12.3 K to 13.2 K (+7.29 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | LINK MAX | Director | Grant | A | 0.00 | 895 | 0 | 59,469 | 58.6 K to 59.5 K (+1.53 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | SVP & General Couns ... | Option Exercise | A | 176.80 | 36,900 | 6,523,920 | 36,900 | |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | SVP & General Couns ... | Grant | A | 0.00 | 2,300 | 0 | 24,532 | 22.2 K to 24.5 K (+10.35 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | SVP, Chief Strat & ... | Option Exercise | A | 176.80 | 36,900 | 6,523,920 | 36,900 | |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | SVP, Chief Strat & ... | Grant | A | 0.00 | 2,300 | 0 | 27,300 | 25 K to 27.3 K (+9.20 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Option Exercise | A | 176.80 | 36,900 | 6,523,920 | 36,900 | |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Sell | S | 174.77 | 305 | 53,305 | 16,760 | 17.1 K to 16.8 K (-1.79 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Grant | A | 0.00 | 3,300 | 0 | 17,065 | 13.8 K to 17.1 K (+23.97 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Option Exercise | A | 176.80 | 49,200 | 8,698,560 | 49,200 | |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Grant | A | 0.00 | 4,000 | 0 | 164,295 | 160.3 K to 164.3 K (+2.50 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Option Exercise | A | 176.80 | 49,200 | 8,698,560 | 49,200 | |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Grant | A | 0.00 | 3,000 | 0 | 28,000 | 25 K to 28 K (+12.00 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Option Exercise | A | 176.80 | 49,200 | 8,698,560 | 49,200 | |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Grant | A | 0.00 | 6,000 | 0 | 119,965 | 114 K to 120 K (+5.26 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | A | 176.80 | 49,200 | 8,698,560 | 49,200 | |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Grant | A | 0.00 | 4,000 | 0 | 108,606 | 104.6 K to 108.6 K (+3.82 %) |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Option Exercise | A | 176.80 | 162,900 | 28,800,720 | 162,900 | |
Mar 04 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Grant | A | 0.00 | 10,100 | 0 | 1,032,331 | 1 M to 1 M (+0.99 %) |
Feb 13 2014 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 174.06 | 2,471 | 430,102 | 4,840 | 7.3 K to 4.8 K (-33.80 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 157.09 | 20 | 3,142 | 986,696 | 986.7 K to 986.7 K (0.00 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Sell | S | 155.55 | 4,600 | 715,530 | 986,716 | 991.3 K to 986.7 K (-0.46 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | CEO | Grant | A | 0.00 | 28,040 | 0 | 991,316 | 963.3 K to 991.3 K (+2.91 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Sell | S | 157.64 | 6 | 946 | 13,765 | 13.8 K to 13.8 K (-0.04 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Sell | S | 155.55 | 1,000 | 155,550 | 13,771 | 14.8 K to 13.8 K (-6.77 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | SVP, Chief HR Offic ... | Grant | A | 0.00 | 6,068 | 0 | 14,771 | 8.7 K to 14.8 K (+69.72 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Wright Frank J | SVP, President Alxn ... | Sell | S | 158.69 | 8 | 1,270 | 19,670 | 19.7 K to 19.7 K (-0.04 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Wright Frank J | SVP, President Alxn ... | Sell | S | 155.55 | 1,090 | 169,550 | 19,678 | 20.8 K to 19.7 K (-5.25 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Wright Frank J | SVP, President Alxn ... | Grant | A | 0.00 | 6,068 | 0 | 20,768 | 14.7 K to 20.8 K (+41.28 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Option Exercise | M | 93.83 | 3,800 | 356,554 | 0 | |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 167.31 | 1,635 | 273,552 | 101,308 | 102.9 K to 101.3 K (-1.59 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 157.51 | 20 | 3,150 | 102,943 | 103 K to 102.9 K (-0.02 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 155.55 | 1,600 | 248,880 | 102,963 | 104.6 K to 103 K (-1.53 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Grant | A | 0.00 | 9,745 | 0 | 104,563 | 94.8 K to 104.6 K (+10.28 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Sell | S | 155.11 | 3,800 | 589,418 | 94,818 | 98.6 K to 94.8 K (-3.85 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | SQUINTO STEPHEN P | EVP, Chief Global O ... | Buy | M | 93.83 | 3,800 | 356,554 | 98,618 | 94.8 K to 98.6 K (+4.01 %) |
Feb 10 2014 | ALXN | ALEXION PHARMACEUT ... | Hallal David | EVP, Chief Commerci ... | Sell | S | 158.05 | 10 | 1,581 | 113,965 | 114 K to 114 K (-0.01 %) |